Certara, Inc. (CERT) — SEC Form D Filing

Certara, Inc. (CERT) filed an SEC Form D on April 28, 2026, reporting $8.62M raised in Pharmaceuticals.

Form D filing details

Filing
SEC Form D
Filing date
April 28, 2026
Amount reported
$8.62M
Round stage
Series A
Industry
Pharmaceuticals
Website
https://www.certara.com/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Current drug development processes are not meeting the demands for speed, innovation, and efficiency necessary for developing new drugs.

Solution

Certara provides predictive simulation, data-driven modeling, and AI solutions to enhance drug discovery, optimize clinical data, and accelerate drug development across all phases, from discovery to market access.

Why now

There is an urgent need for faster, more innovative drug development solutions to meet the rising demands of the healthcare sector.

Verdict

Investors said yes at that moment because the narrative addressed a pressing need for efficiency in drug development, not because similar companies had cleared the market before. They were betting on the potential of advanced technology like predictive simulations and AI to transform an outdated system. The limited upside lies in the crowded nature of the pharmaceutical technology space, where numerous players are already established, reducing the durability of any competitive advantage.

Source: SEC EDGAR Form D filing